Going global: are ambitious biotechs biting off more than they can chew?

As breakthrough drug companies look to new geographic markets, including emerging economies to target populations with rare diseases, many are coming up against unforeseen or underestimated barriers. Here, Arriello’s Kate Coleman reviews the findings of new transatlantic research which charts biotechs’ evolving commercialisation strategies and regulatory preparations, and the realities they are experiencing. 

The global biotech opportunity was worth an estimated $1.55 trillion worldwide in 2023, and is projected to grow at a compound annual rate of 13.96% between now and 20301….